MLN3126

立即咨询

MLN3126

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

628300-71-0

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议
200mg	电议

产品介绍

MLN3126 是一种具有口服活性的强效CCR9拮抗剂。 MLN3126 抑制 CCL25 诱导的钙动员 (calcium mobilization) 和小鼠初级胸腺细胞趋化 (chemotaxis)，抑制钙内流的IC₅₀为 6.3 nM。

生物活性

MLN3126 is an orally active and potentCCR9antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht anIC₅₀value of 6.3 nM forcalcium influx^[1].

体外研究
(In Vitro)

MLN3126 inhibits CCL25-induced calcium mobilization with an IC₅₀value of 6.3 nM in CCR9 expressing cells^[1].
MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC₅₀of 14.2 nM^[1].

Cell Invasion Assay^[1]

Cell Line:	Mouse thymocytes
Concentration:	0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:	90 min
Result:	Inhibited CCL25-induced chemotaxis of mouse thymocytes.

体内研究
(In Vivo)

MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells^[1].
MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD)^[1].

Animal Model:	Activated T cell transferred colitis mouse model^[1]
Dosage:	0.05, 0.25 and 1% (w/w) (around 4 g/day)
Administration:	Oral gavage; 21 days
Result:	Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.

Clinical Trial

分子量

446.90

性状

Solid

Formula

C₂₁H₁₉ClN₂O₅S

CAS 号

628300-71-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 25 mg/mL(55.94 mM;ultrasonic and warming and heat to 60℃)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	2.2376 mL	11.1882 mL	22.3764 mL
5 mM	0.4475 mL	2.2376 mL	4.4753 mL
10 mM	0.2238 mL	1.1188 mL	2.2376 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。